Literature DB >> 6208749

Tumour markers in testicular germ cell tumours. Five-year experience from the DATECA Study 1976-1980.

B Nørgaard-Pedersen, H P Schultz, J Arends, H Brincker, G Krag Jacobsen, B Lindeløv, M Rørth, I L Svennekjaer.   

Abstract

Since Jan. 1, 1976, nearly all new cases of testicular germ cell tumours have been included in the Danish Testicular Carcinoma Study (DATECA), and have been monitored by the tumour markers alpha-fetoprotein (AFP) and human chorionic gonadotropin (HCG). During the first five years, 1058 patients participated in the investigation, but only 603 of these patients were followed by preoperative as well as postoperative marker determinations in serum. The overall prevalence of marker positivity, i.e. elevated preoperative values for AFP and/or HCG, was 8 per cent for seminoma patients and 60 per cent for non-seminoma patients. Elevated levels of serum AFP and HCG were correlated to the presence of endodermal sinus tumour and choriocarcinoma elements, respectively, in the primary tumour. The presence of increased marker concentration in serum was correlated stage (higher percentage in higher stages) and to prognosis (marker negative patients had a better prognosis than marker positive patients). Marker production by seminoma patients seems to indicate a poor prognosis, especially for HCG producing seminomas.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6208749     DOI: 10.3109/02841868409136024

Source DB:  PubMed          Journal:  Acta Radiol Oncol        ISSN: 0349-652X


  8 in total

1.  Treatment of stage I seminoma: should beta-HCG positive seminoma be treated aggressively?

Authors:  K Suzuki; H Nakazato; K Kurokawa; T Suzuki; K Suzuki; H Yamanaka
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

Review 2.  Seminoma testis with elevated serum beta-HCG--a category of germ-cell cancer between seminoma and nonseminoma.

Authors:  K P Dieckmann; W Düe; H W Bauer
Journal:  Int Urol Nephrol       Date:  1989       Impact factor: 2.370

Review 3.  Optimal drug therapy in the treatment of testicular cancer.

Authors:  E R Priest; N J Vogelzang
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

Review 4.  Biomarkers of disease recurrence in stage I testicular germ cell tumours.

Authors:  Peter Lesko; Michal Chovanec; Michal Mego
Journal:  Nat Rev Urol       Date:  2022-08-26       Impact factor: 16.430

5.  Frequency of serum tumour marker monitoring in patients with non-seminomatous germ cell tumours.

Authors:  M J Seckl; G J Rustin; K D Bagshawe
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640

6.  Serum Tumour Markers in Testicular Germ Cell Tumours: Frequencies of Elevated Levels and Extents of Marker Elevation Are Significantly Associated with Clinical Parameters and with Response to Treatment.

Authors:  Klaus-Peter Dieckmann; Hanna Simonsen-Richter; Magdalena Kulejewski; Petra Anheuser; Henrik Zecha; Hendrik Isbarn; Uwe Pichlmeier
Journal:  Biomed Res Int       Date:  2019-05-28       Impact factor: 3.411

7.  Testicular germ cell tumors type 2 have high RNA expression of LDHB, the gene for lactate dehydrogenase subunit B.

Authors:  Finn Edler von Eyben; Jorge Parraga-Alava; Shi-Ming Tu
Journal:  Asian J Androl       Date:  2021 Jul-Aug       Impact factor: 3.285

Review 8.  Persistently elevated alpha-fetoprotein associated with chronic hepatitis B during chemotherapy for malignant ovarian germ cell tumors: a case series and a review of the literature.

Authors:  Xuan Zong; Jia-Xin Yang; Ying Zhang
Journal:  J Ovarian Res       Date:  2019-12-13       Impact factor: 4.234

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.